1. An apparatus for detecting network congestion based on a destination node, comprising:
a physical information extraction unit configured to extract physical information of an electrical signal received through an antenna of the destination node;
a MAC information extraction unit configured to extract a size of a MAC frame payload from a MAC frame on the basis of the extracted physical information;
a TCP information extraction unit configured to extract a size of service data included in the MAC frame payload;
a data size comparison unit configured to compare the size of the MAC frame payload with the size of the service data and generate comparison result data; and
a congestion detection unit configured to receive the comparison result data from the data size comparison unit, compare the comparison result data with a predetermined threshold value, and determine presence or absence of network congestion.
2. The apparatus according to claim 1,
wherein the MAC information extraction unit extracts the size of the MAC frame payload when it is confirmed that the received electrical signal is data to be transmitted to the destination node by using address information recorded in a MAC frame header.
3. The apparatus according to claim 1, wherein the data size comparison unit calculates a ratio between the size of the MAC frame payload and the size of the service data, and
the comparison result data include the calculated ratio.
4. The apparatus according to claim 3,
wherein the data size comparison unit calculates the ratio according to the following Equation:
R
MAC
TCP
=
CS
MAC
CS
TCP
APP
,
and
wherein RMACTCP represents a calculated congestion ratio, CSMAC represents a cumulative size of data with respect to a payload obtained from a MAC frame of a data link layer, and CSTCPAPP represents a cumulative size of data with respect to service data obtained from a transport layer or an application layer.
5. The apparatus according to claim 1, wherein at least one of the data size comparison unit and the congestion detection unit operates in at least any one of a transport layer and an application layer of the destination node.
6. A method for detecting network congestion based on a destination node by using an apparatus for detecting network congestion based on a destination node, comprising:
extracting physical information of an electrical signal received through an antenna of the destination node;
extracting a size of a MAC frame payload from a MAC frame on the basis of the extracted physical information;
extracting a size of service data included in the MAC frame payload;
comparing the size of the MAC frame payload with the size of the service data and generating comparison result data; and
comparing the generated comparison result data with a predetermined threshold value to determine presence or absence of network congestion.
7. The method according to claim 6, wherein the step of extracting a size of service data includes extracting a size of service data of a data frame present in a transport layer or an application layer.
8. The method according to claim 6, wherein the step of extracting a size of service data includes extracting a size of service data by using data offset information and a sequence number recorded in a TCP header.
9. The method according to claim 6, wherein the step of extracting a size of a MAC frame payload includes extracting a size of a payload of the MAC frame by reading the MAC frame without damaging the MAC frame and transferring the MAC frame to its upper layer as it is.
10. The method according to claim 6, wherein the step of generating comparison result data includes generating comparison result data by calculating a ratio between the size of the MAC frame payload and the size of the service data.
11. The method according to claim 10,
wherein the step of generating comparison result data includes calculating the ratio according to the following Equation:
R
MAC
TCP
=
CS
MAC
CS
TCP
APP
,
and
wherein RMACTCP represents a calculated congestion ratio, CSMAC represents a cumulative size of data with respect to a payload obtained from a MAC frame of a data link layer, and CSTCPAPP represents a cumulative size of data with respect to service data obtained from a transport layer or an application layer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-45. (canceled)
46. A method of providing a darker skin tint that emulates a healthy suntan, comprising:
ingesting at least about 20 milligrams per day of zeaxanthin to cause a noticeable darkening of skin tint, the ingested zeaxanthin being in a formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin in the formulation being predominantly present in the form of the R-R stereoisomer of zeaxanthin; and
after the noticeable darkening of the skin tint has been achieved, continuing to ingest at least about 20 milligrams per day of zeaxanthin from the formulation so as to maintain a darker skin tint.
47. The method of claim 46, wherein the noticeable darkening of skin tint is noticeable to a person who uses a printed color strip that enables comparison of skin tint prior to ingesting zeaxanthin, to skin tint of the same person after ingestion of the zeaxanthin.
48. The method of claim 46, wherein the formulation containing the zeaxanthin is ingested by an adult in a quantity that ranges from about 30 to about 100 milligrams of zeaxanthin per day, for a sufficient number of days to cause the noticeable darkening of skin tint.
49. The method of claim 46, wherein zeaxanthin is ingested in a quantity that is sufficient to cause the noticeable darkening of skin tint by at least two color shades, when measured using a color chart used by dermatologists and comparing post-ingestion skin color of a person taking zeaxanthin to pre-ingestion skin color of the person.
50. The method of claim 46, wherein the zeaxanthin is formulated in the formulation in an oily carrier substance.
51. The method of claim 46, further including ingesting at least one second active agent in a dosage that is believed to induce darker skin tint in at least some people.
52. The method of claim 51, wherein the second agent is selected from the group consisting of melanocyte-stimulating hormone and analogs, non-zeaxanthin carotenoids, tyrosine, green tea extract, lutein, lipoic acid, and selenomethionine.
53. The method of claim 51, wherein the at least one second agent is present in the formulation.
54. The method of claim 51, wherein the zeaxanthin is the predominate carotenoid in the formulation.
55. The method of claim 46, further including exposing at least one area of skin to ultraviolet radiation at a level which induces melanin production within the exposed area of skin, thereby creating a combination of elevated zeaxanthin concentration and elevated melanin levels in one or more epidermal layers in the exposed area of skin.
56. The method of claim 46, wherein the formulation is presented in the form of capsules and the ingesting at least about 20 milligrams per day of zeaxanthin is achieved by taking multiple capsules per day.
57. The method of claim 46, wherein the initial ingesting of the formulation and the continued ingesting of the formulation after the noticeable darkening of the skin tint has been achieved are at in different amounts of zeaxanthin per day.
58. The method of claim 57, wherein the continued ingesting of the formulation after the noticeable darkening of the skin tint has been achieved is at 20 milligrams per day of zeaxanthin.
59. The method of claim 46, wherein the zeaxanthin is the predominate carotenoid in the formulation.
60. The method of claim 59, wherein the formulation further includes lutein.
61. A method of providing a darker skin tint that emulates a healthy suntan, comprising:
ingesting at least about 20 milligrams per day of zeaxanthin to cause a noticeable darkening of the skin by a single color shade as measured on a skin-color chart, the ingested zeaxanthin being in a formulation that is one of a group consisting of a capsule, a tablet, and a liquid, the zeaxanthin in the formulation being predominantly present in the form of the R-R stereoisomer of zeaxanthin; and
after the darkening of skin tint by the single color shade on the skin-color chart, continuing to ingest the formulation so as to ingest at least about 20 milligrams per day of zeaxanthin to cause at least a two-color shade difference from the pre-ingestion skin color of the person when measured on the skin-color chart.
62. The method of claim 61, wherein the formulation includes at least one second active agent in a dosage that is believed to induce darker skin tint.
63. The method of claim 62, wherein the second agent is selected from the group consisting of melanocyte-stimulating hormone and analogs, non-zeaxanthin carotenoids, tyrosine, green tea extract, lutein, lipoic acid, and selenomethionine.
64. The method of claim 61, further including exposing at least one area of skin to ultraviolet radiation at a level that induces melanin production within the exposed area of skin, thereby creating a combination of elevated zeaxanthin concentration and elevated melanin concentration in one or more epidermal layers in the exposed area of skin.
65. The method of claim 61, wherein the formulation is presented in the form of capsules and the ingesting at least about 20 milligrams per day of zeaxanthin is achieved by taking between two and ten capsules.
66. The method of claim 61, wherein the zeaxanthin is the predominate carotenoid in the formulation.